Phosphoinositide-3-Kinase Regulatory Subunit 2 (PIK3R2, also known as p85-beta) is a critical regulatory component of the Class IA PI3K pathway. By stabilizing the p110 catalytic subunit and mediating its recruitment to activated receptor tyrosine kinases (RTKs), PIK3R2 serves as a molecular switch in oncogenic signaling, metabolic regulation, and developmental disorders. As therapeutic strategies shift toward isoform-selective PI3K modulation and targeted protein degradation (PROTACs), high-purity reagents are essential to resolve the structural complexities of the PI3K regulatory-catalytic interface.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PIK3R2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PIK3R2 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW confirmed by SDS-PAGE. Suitable for biochemical interaction and structural studies. |
View PIK3R2 Products |
| Gene Delivery | PIK3R2 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation, enabling downstream AKT phosphorylation readouts in native cellular contexts. |
View PIK3R2 Products |
| Benchmark Ab | Anti-PIK3R2 Recombinant Antibody Sequence-verified positive control for Western Blot, ELISA, and immunoprecipitation assays. |
View PIK3R2 Products |
| Validator | PIK3R2 siRNA Set Target-specific siRNA sequences for functional knockdown verification and pathway specificity controls. |
View PIK3R2 Products |
| Related Target A | PIK3CA The catalytic subunit p110-alpha. Co-targeting or co-expressing p110-alpha with PIK3R2 is essential for reconstituting active Class IA PI3K enzyme complexes. |
View PIK3CA Products |
| Related Target B | PIK3R1 The p85-alpha regulatory subunit. Critical for counter-screening and selectivity profiling to avoid off-target metabolic toxicity. |
View PIK3R1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Resolving p85α (PIK3R1) vs. p85β (PIK3R2) Selectivity | Highly purified, sequence-verified homologous protein panels for precise off-target counter-screening. |
| Reconstituting Functional heterodimers | High-purity recombinant PIK3R2 and catalytic partners (PIK3CA) expressed with native-like post-translational profiles. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and recombinant positive controls included. |
| False Positives in Screening | Multi-sequence validated siRNA knockdown pools included for target-specific validation. |
Live PIK3R2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PI3K pathway therapeutics is intensifying, with major players shifting focus from pan-PI3K inhibitors to isoform-selective modulators and targeted protein degraders (PROTACs). While early-generation pan-inhibitors faced dose-limiting toxicities—often due to off-target inhibition of PIK3R1-associated metabolic pathways—the next wave of R&D targets the regulatory subunit PIK3R2 to selectively disrupt oncogenic scaffolding without perturbing systemic glucose homeostasis. Disrupting the specific interaction between PIK3R2 and its catalytic partners represents a highly selective therapeutic window in solid tumors overexpressing p85-beta.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitors) | Novartis, Genentech, Academic Consortia | Breast Cancer, Endometrial Cancer, MPPH Syndrome | Selectivity Assay (Need high-purity PIK3R2 vs. PIK3R1 proteins to verify isoform-specific disruption) |
| PROTACs / Degraders | Arvinas, Kymera Therapeutics, Seed Therapeutics | Refractory Solid Tumors, Lymphomas | Ubiquitination & Binding Kinetics (Need sequence-verified PIK3R2 for SPR/FP ternary complex assays) |
| RNAi / Antisense | Alnylam Pharmaceuticals, Ionis Pharmaceuticals | Megalencephaly-Polymicrogyria (MPPH) | Knockdown Validation (Need Lentivirus for stable cell lines and validated siRNA validation controls) |